Competitor Analysis- Cancer Vaccines, New Report Launched

The present Competitive Intelligence report about Cancer Vaccines provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Projects are listed according to their main antigenic constituents: peptides, recombinant proteins, idiotype antibody, DNA (plasmid, expression vector), RNA, virus-like particles (VLP), dendritic cells, tumor cells (tumor cell lines), microorganism-based and others.

Of the 140 clinical stage cancer vaccines, three were approved and are commercialized in the major pharmaceutical markets with combined 2013 sales of US$ 2,385 mln. Peptides and proteins make out 43% of clinical stage cancer vaccines, followed by dendritic cell and tumor cell (line)-based cancer vaccines with each contributing 15% to the clinical cancer vaccine pipeline. DNA- and RNA-based cancer vaccines maked out 17% of the clinical portfolio.

The report includes a compilation of currently active projects in research and development for prophylaxis and therapy of cancer. In addition, the report lists company-specific R&D pipelines of cancer vaccines. Competitor projects are listed in a tabular format providing information on:

• Drug Codes
• Target / Mechanism of Action
• Class of Compound
• Company
• Product Category
• Indication
• R&D Stage and

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Spanning Over 179 pages , “Competitor Analysis- Cancer Vaccines” report covering the Cancer Vaccines by Main Composition (Peptide-based Cancer Vaccines, Protein-based Cancer Vaccines, Idiotype Antibody-based Cancer Vaccines, DNA-based Cancer Vaccines: naked and virally vectored, RNA-based Cancer Vaccines, Virus-Like Particle (VLP)-based Cancer Vaccines, Dendritic Cell-based Cancer Vaccines, Tumor Cell and Tumor Cell Line – based Cancer Vaccines, Microorganism-based Cancer Vaccines, Other and Not Defined Cancer Vaccines), Corporate Cancer Vaccines R&D Pipelines. The report covered companies Partial List - ABIVAX, Activartis, Aduro BioTech, Advanced Cancer Therapeutics, Advaxis, Aeterna Zentaris, Agenus, Antigen Express, ApoVax, Ascend Biopharmaceuticals, Asterias Biotherapeutics, Avax Technologies, Bavarian Nordic.

See more at: http://mrr.cm/Z3h   

Find other Biotechnology Reports at : 

http://www.marketresearchreports.com/biotechnology

For regular industry updates subscribe to our newsletter at: 

http://www.marketresearchreports.com/subscribe-to-newsletter